SMT202000222T1 - Adenovirus oncolitico che codifica per una proteina b7 - Google Patents

Adenovirus oncolitico che codifica per una proteina b7

Info

Publication number
SMT202000222T1
SMT202000222T1 SM20200222T SMT202000222T SMT202000222T1 SM T202000222 T1 SMT202000222 T1 SM T202000222T1 SM 20200222 T SM20200222 T SM 20200222T SM T202000222 T SMT202000222 T SM T202000222T SM T202000222 T1 SMT202000222 T1 SM T202000222T1
Authority
SM
San Marino
Prior art keywords
protein
oncolytic adenovirus
adenovirus encoding
encoding
oncolytic
Prior art date
Application number
SM20200222T
Other languages
English (en)
Italian (it)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of SMT202000222T1 publication Critical patent/SMT202000222T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20200222T 2015-04-30 2016-04-29 Adenovirus oncolitico che codifica per una proteina b7 SMT202000222T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein
EP16723043.2A EP3288573B1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Publications (1)

Publication Number Publication Date
SMT202000222T1 true SMT202000222T1 (it) 2020-05-08

Family

ID=56008588

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200222T SMT202000222T1 (it) 2015-04-30 2016-04-29 Adenovirus oncolitico che codifica per una proteina b7

Country Status (31)

Country Link
US (6) US11000559B2 (https=)
EP (2) EP3288573B1 (https=)
JP (3) JP6931229B2 (https=)
KR (4) KR20250134212A (https=)
CN (2) CN108396015B (https=)
AU (3) AU2016256582B2 (https=)
BR (2) BR112017023171A2 (https=)
CA (1) CA2984038C (https=)
CL (2) CL2017002731A1 (https=)
CO (1) CO2017010831A2 (https=)
CY (1) CY1122833T1 (https=)
DK (1) DK3288573T3 (https=)
EA (1) EA037611B1 (https=)
ES (1) ES2780366T3 (https=)
HR (1) HRP20200439T1 (https=)
HU (1) HUE048320T2 (https=)
IL (3) IL284375B (https=)
LT (1) LT3288573T (https=)
MX (1) MX2017013684A (https=)
MY (1) MY183703A (https=)
PE (2) PE20180241A1 (https=)
PH (1) PH12017501942A1 (https=)
PL (1) PL3288573T3 (https=)
PT (1) PT3288573T (https=)
RS (1) RS60105B1 (https=)
SA (2) SA517390260B1 (https=)
SG (3) SG11201708604TA (https=)
SI (1) SI3288573T1 (https=)
SM (1) SMT202000222T1 (https=)
WO (1) WO2016174200A1 (https=)
ZA (1) ZA201801589B (https=)

Families Citing this family (40)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671558C2 (ru) 2013-06-14 2018-11-02 ŠŸŃŠ°Š¹Š¾Šŗсус Š¢ŠµŃ€Š°ŠæьютŠøŠŗс Š›ŠøŠ¼ŠøтŠµŠ“ Š ŠµŠ¶ŠøŠ¼ Š²Š²ŠµŠ“ŠµŠ½Šøя Šø сŠ¾ŃŃ‚Š°Š²Ń‹ Š“Š»Ń Š°Š“ŠµŠ½Š¾Š²ŠøрусŠ¾Š² тŠøŠæŠ° Š²
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
EA201891022A1 (ru) * 2015-12-17 2019-01-31 ŠŸŃŠ°Š¹Š¾Šŗсус Š¢ŠµŃ€Š°ŠæьютŠøŠŗс Š›ŠøŠ¼ŠøтŠµŠ“ Š’Šøрус, ŠŗŠ¾Š“ŠøрующŠøŠ¹ Š°Š½Ń‚ŠøтŠµŠ»Š¾ Šŗ ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗсу tcr ŠøŠ»Šø фрŠ°Š³Š¼ŠµŠ½Ń‚ уŠŗŠ°Š·Š°Š½Š½Š¾Š³Š¾ Š°Š½Ń‚ŠøтŠµŠ»Š°
EP3436591B1 (en) * 2016-03-31 2023-01-04 The European Molecular Biology Laboratory Adenoviral coat protein derived delivery vehicles
CN119614520A (zh) 2016-08-29 2025-03-14 é˜æ協ē±³ę–Æē”Ÿē‰©å…¬åø ęŗåø¦åŒē‰¹å¼‚ꀧtē»†čƒžč””ꎄå™Øēš„č…ŗē—…ęƒ
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP4282969A3 (en) * 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
EP4023233B1 (en) * 2016-09-27 2026-01-07 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
US12350303B2 (en) * 2017-02-03 2025-07-08 University of Pittsburghā€”of the Commonwealth System of Higher Education Oncolytic virus therapy
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
WO2018218151A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
CA3064863A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
PL3630143T3 (pl) 2017-06-01 2023-10-30 Akamis Bio Limited Wirus onkolityczny i sposĆ³b
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
CN118001307A (zh) * 2018-03-30 2024-05-10 č—¤å ‚å…·ēŗŖ č‚æčƒ€å‘ē”ŸęŠ‘制型ęŗ¶ē˜¤ē—…ęƒ
CN119955743A (zh) * 2018-09-10 2025-05-09 äøŠęµ·é”¦ę–Æē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø äæ®é„°ēš„ęŗ¶ē˜¤ē—…ęÆ’ć€å…¶ē»„合ē‰©å’Œē”Ø途
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
AU2020232264B2 (en) * 2019-03-05 2026-02-19 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2022252185A1 (zh) * 2021-06-03 2022-12-08 äøŠęµ·å…č‹±ē”Ÿē‰©åŒ»čÆē§‘ęŠ€ęœ‰é™å…¬åø ęŗ¶ē˜¤ē—…ęÆ’č½½ä½“åŠå…¶åŗ”ē”Ø
EP4404947A4 (en) 2021-09-23 2025-12-10 Sagittarius Bio Inc Adenovirus and Methods of Using Adenovirus
US20250215452A1 (en) * 2022-03-25 2025-07-03 UniversitƤt ZĆ¼rich Adenoviral Mediated Targeting of Activated Immune Cells
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thƩrapie gƩnique.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composiĆ§Ć£o farmaceutica
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 ę˜‚å°¼å…‹ę–ÆčÆē‰©å…¬åø ē”ØäŗŽč‚æē˜¤ę²»ē–—和预防ēš„臓ē»†čƒžē—…变ē—…ęƒ
ATE374821T1 (de) 1997-02-20 2007-10-15 Univ Johns Hopkins Med Mutationen in atp-abhƤngigen transpositionsproteinen die die zielortspezifitƤt reduzieren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 ę­å·žčµ›ē‹®ē”Ÿē‰©ęŠ€ęœÆå¼€å‘ęœ‰é™å…¬åø åŸŗå› å·„ē؋č…ŗē—…ęƒ及其ē”Ø途
EP1112372A1 (en) 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
EP1137792B9 (en) 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
AU5464000A (en) 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
DE60115600T2 (de) * 2000-01-21 2006-07-20 Biovex Ltd. VirusstƤmme fĆ¼r die onkolytische behandlung von krebs
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
WO2003064666A1 (en) * 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔Ā·ę¾å†…Ā·éœå°”姆 å…·ęœ‰åå‘åŸŗ因č”Øč¾¾ēš„č…ŗē—…ęƒ及其åŗ”ē”Ø
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2004260044B2 (en) 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US7510868B2 (en) 2004-05-26 2009-03-31 Paul Harden Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 ęˆéƒ½åŗ·å¼˜ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø č‚æē˜¤ē»†čƒžäø“äø€č”Øč¾¾å…ē–«č°ƒčŠ‚因子gm-csfēš„ęŗ¶ē˜¤ę€§č…ŗē—…ęƒ重ē»„体ēš„ęž„å»ŗ及其åŗ”ē”Ø
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 ē»†čƒžåŸŗ因ē³»ē»Ÿęœ‰é™å…¬åø ē”ØäŗŽč‚æē˜¤ē»†čƒžå¢žå¼ŗč½¬åƼēš„ēŗ¤ē»“äæ®é„°ēš„č…ŗē—…ęÆ’č½½ä½“
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 UniversitƤt Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP5448840B2 (ja) 2006-12-22 2014-03-19 ćƒ—ć‚·ć‚Ŗć‚Æć‚µć‚¹ćƒ»ć‚»ćƒ©ćƒ”ćƒ„ćƒ¼ćƒ†ć‚£ć‚Æć‚¹ćƒ»ćƒŖ惟惆惃惉 č…«ē˜é€€ēø®ć‚¢ćƒ‡ćƒŽć‚¦ć‚¤ćƒ«ć‚¹ć®ä½œå‡ŗćŠć‚ˆć³ćć®ä½æē”Ø
MX339014B (es) 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
CN101381742A (zh) 2008-10-23 2009-03-11 ęµ™ę±Ÿē†å·„大学 ꙚꜟåÆåŠØå­é¶å‘ę€§č°ƒęŽ§ęŗ¶ē˜¤č…ŗē—…ęƒpCN305č½½ä½“åŠå…¶ęž„å»ŗę–¹ę³•äøŽåŗ”ē”Ø
ES2385251B1 (es) * 2009-05-06 2013-05-06 FundaciĆ³ Privada Institut D'investigaciĆ³ BiomĆØdica De Bellvitge Adenovirus oncolĆ­ticos para el tratamiento del cĆ”ncer.
US20120283318A1 (en) * 2009-10-05 2012-11-08 Mei Ya-Fang Replicating viral vectors for gene therapy
WO2012024351A2 (en) 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
RU2013118724A (ru) * 2010-09-24 2014-10-27 ŠžŠ½ŠŗŠ¾Ń Š¢ŠµŃ€Š°ŠæьютŠøŠŗс ŠžŠ¹ ŠžŠ½ŠŗŠ¾Š»ŠøтŠøчŠµŃŠŗŠøŠµ Š°Š“ŠµŠ½Š¾Š²ŠøрусŠ½Ń‹Šµ Š²ŠµŠŗтŠ¾Ń€Ń‹ Šø сŠ²ŃŠ·Š°Š½Š½Ń‹Šµ с Š½ŠøŠ¼Šø сŠæŠ¾ŃŠ¾Š±Ń‹ Šø ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
KR20130108371A (ko) 2010-09-24 2013-10-02 ģ˜Øģ½”ģŠ¤ ķ…Œė¼ķ“Øķ‹±ģŠ¤ ģ˜¤ģ™€ģ“ ė‹Øķ“ė”  ķ•­ā€•ļ½ƒļ½”ļ½Œļ½ļ¼ļ¼” ķ•­ģ²“ė„¼ ģ•”ķ˜øķ™”ķ•˜ėŠ” ģ¢…ģ–‘ė¶„ķ•“ ģ•„ė°ė…øė°”ģ“ėŸ¬ģŠ¤ ė²”ķ„°
US20140316369A1 (en) 2011-11-14 2014-10-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕č„æåøˆčŒƒå¤§å­¦ äø€ę­„ę³•ęž„å»ŗęŗåø¦å¤–ęŗåŸŗ因ēš„d24ēŗ¤ē»“蛋ē™½äæ®é„°ēš„ę”件复制型č…ŗē—…ęÆ’č½½ä½“åŠå…¶åŗ”ē”Ø
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN121592718A (zh) 2015-03-17 2026-03-03 å€¾ę–œē”Ÿē‰©åŒ»ē–—å…¬åø ē¼–ē åŒē‰¹å¼‚ę€§ęŠ—ä½“ēš„ęŗ¶ē˜¤č…ŗē—…ęƒ及äøŽå…¶ē›ø关ēš„ę–¹ę³•å’Œē”Ø途
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
EA201891022A1 (ru) 2015-12-17 2019-01-31 ŠŸŃŠ°Š¹Š¾Šŗсус Š¢ŠµŃ€Š°ŠæьютŠøŠŗс Š›ŠøŠ¼ŠøтŠµŠ“ Š’Šøрус, ŠŗŠ¾Š“ŠøрующŠøŠ¹ Š°Š½Ń‚ŠøтŠµŠ»Š¾ Šŗ ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗсу tcr ŠøŠ»Šø фрŠ°Š³Š¼ŠµŠ½Ń‚ уŠŗŠ°Š·Š°Š½Š½Š¾Š³Š¾ Š°Š½Ń‚ŠøтŠµŠ»Š°
US20210198689A1 (en) 2016-03-18 2021-07-01 Nant Holdings Ip, Llc Multimodal Vector for Dendritic Cell Infection
CN119614520A (zh) 2016-08-29 2025-03-14 é˜æ協ē±³ę–Æē”Ÿē‰©å…¬åø ęŗåø¦åŒē‰¹å¼‚ꀧtē»†čƒžč””ꎄå™Øēš„č…ŗē—…ęƒ
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3040296A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
PL3630143T3 (pl) * 2017-06-01 2023-10-30 Akamis Bio Limited Wirus onkolityczny i sposĆ³b
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
US20180140649A1 (en) 2018-05-24
CA2984038A1 (en) 2016-11-03
CL2017002731A1 (es) 2018-06-08
US20170266243A1 (en) 2017-09-21
US20190076493A1 (en) 2019-03-14
LT3288573T (lt) 2020-03-25
JP2021176339A (ja) 2021-11-11
CN107690479A (zh) 2018-02-13
SI3288573T1 (sl) 2020-06-30
EP3288573B1 (en) 2020-02-12
KR20180022638A (ko) 2018-03-06
US20170056458A1 (en) 2017-03-02
IL255286B (en) 2021-01-31
PL3288573T3 (pl) 2020-05-18
IL258044A (en) 2018-05-31
IL255286A0 (en) 2017-12-31
CN107690479B (zh) 2022-02-18
AU2016256582A8 (en) 2018-01-18
KR102854512B1 (ko) 2025-09-04
CY1122833T1 (el) 2021-05-05
KR102643574B1 (ko) 2024-03-06
PE20180241A1 (es) 2018-01-31
SG11201708604TA (en) 2017-11-29
SA520412637B1 (ar) 2022-03-01
IL258044B (en) 2021-07-29
HRP20200439T1 (hr) 2020-06-12
PH12017501942A1 (en) 2018-03-19
HK1249009A1 (en) 2018-10-26
IL284375B (en) 2022-07-01
ES2780366T3 (es) 2020-08-25
AU2020223665A1 (en) 2020-09-10
AU2016256582B2 (en) 2020-10-29
US10322152B2 (en) 2019-06-18
US11000559B2 (en) 2021-05-11
EP3288573A1 (en) 2018-03-07
SG10201901482XA (en) 2019-03-28
BR122018004815A2 (pt) 2019-09-10
US20210338753A1 (en) 2021-11-04
US10548929B2 (en) 2020-02-04
KR20180118249A (ko) 2018-10-30
EP3391892A1 (en) 2018-10-24
JP6931229B2 (ja) 2021-09-01
JP2018514199A (ja) 2018-06-07
CO2017010831A2 (es) 2018-02-28
EA037611B1 (ru) 2021-04-21
KR20240032177A (ko) 2024-03-08
PT3288573T (pt) 2020-03-25
US10124028B2 (en) 2018-11-13
CN108396015B (zh) 2022-02-18
HUE048320T2 (hu) 2020-07-28
DK3288573T3 (da) 2020-03-16
AU2018201446B2 (en) 2020-05-28
JP7162929B2 (ja) 2022-10-31
US20180042973A1 (en) 2018-02-15
PE20181140A1 (es) 2018-07-17
CL2018000587A1 (es) 2018-08-10
JP6928380B2 (ja) 2021-09-01
SA517390260B1 (ar) 2021-11-10
AU2016256582A1 (en) 2017-11-16
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
EA201791971A1 (ru) 2018-04-30
JP2018139586A (ja) 2018-09-13
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
AU2018201446A1 (en) 2018-03-29
MY183703A (en) 2021-03-09
CN108396015A (zh) 2018-08-14
CA2984038C (en) 2023-01-03
WO2016174200A1 (en) 2016-11-03
ZA201801589B (en) 2019-10-30
BR112017023171A2 (pt) 2018-07-17
IL284375A (en) 2021-07-29
RS60105B1 (sr) 2020-05-29

Similar Documents

Publication Publication Date Title
IL258044A (en) Oncolytic adenovirus encoding the b7 protein
IL260027A (en) A group b adenovirus that encodes an anti-tcr-complex antibody or particle
ZA201802261B (en) Polypeptides
PL3659614T3 (pl) Onkolityczny wirus krowianki
IL254577A0 (en) polypeptides
GB201713765D0 (en) Modified adenovirus
GB201409634D0 (en) Intra block copy mode encoding choice
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
SG11201706882VA (en) Polypeptides
ZA201704366B (en) Il-17a-binding polypeptides
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORĪ³)
GB201417535D0 (en) Adapting encoding properties
IL267267A (en) Vibration sensing system with wavelength encoding
GB201401877D0 (en) Peptides
EP3239962A4 (en) Encoding device
GB2539417B (en) Optimized multi-view image encoding
GB201520655D0 (en) Multi-mode sensor
GB201614607D0 (en) Modified adenovirus
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
GB201401159D0 (en) Adenovirus
GB201516655D0 (en) IX sensor
GB201502178D0 (en) Detecting polypeptides